Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

about

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

Item

http://www.wikidata.org/entity/Q55191884

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@en

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@nl

type

Item

label

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@en

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@nl

prefLabel

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@en

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@nl

P1476

Resistance to epidermal growth ...... s, T790M, and clinical trials.

@en

P2093

G M O'Kane

http://www.w3.org/2001/XMLSchema#string

N B Leighl

http://www.w3.org/2001/XMLSchema#string

T A Barnes

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

P304

S28-S37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.3796

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29910645

http://www.w3.org/2001/XMLSchema#string

P932

6001758

http://www.w3.org/2001/XMLSchema#string